Ascentage Pharma Reports 110% Product Sales Growth, Successful New Drug Launch, and US$322.6M Capital Infusion

summarizeSummary

Ascentage Pharma reported a 110% year-over-year increase in product sales to US$72.3 million for 2025, driven by strong Olverembatinib growth and the successful launch of Lisaftoclax, while also significantly boosting cash reserves through US$322.6 million in equity offerings.

check_boxKey Events

• Strong Product Sales Growth

  Product sales increased by 110% to US$72.3 million in 2025, driven by Olverembatinib's 80.6% growth after its inclusion in China's National Reimbursement Drug List (NRDL).

• Successful New Product Launch

  Lisaftoclax, approved in July 2025, generated US$10.1 million in sales in its first five months, marking it as the first Bcl-2 inhibitor conditionally approved in China.

• Significant Capital Raises

  The company raised US$132.5 million from a U.S. IPO and US$190.1 million from a follow-on offering, increasing cash and bank balances to US$353.2 million.

• Advancing Clinical Pipeline

  Nine global registrational Phase III trials are underway for key drug candidates, with multiple FDA/EMA clearances and a Breakthrough Therapy Designation for Olverembatinib.

auto_awesomeAnalysis

Ascentage Pharma demonstrated strong commercial execution in 2025, with product sales increasing by 110% year-over-year to US$72.3 million. This growth was primarily fueled by an 80.6% increase in Olverembatinib sales following its inclusion in China's National Reimbursement Drug List (NRDL), and the successful launch of Lisaftoclax, which generated US$10.1 million in its first five months. The company also significantly strengthened its financial position by raising US$322.6 million through a U.S. IPO and a follow-on offering, increasing cash and bank balances to US$353.2 million. This substantial capital infusion provides a strong runway for continued R&D and commercialization efforts. While the net loss for the year increased to US$177.7 million due to higher R&D and selling expenses, this reflects aggressive investment in advancing a robust pipeline, including nine global registrational Phase III trials for its key drug candidates. The progress in clinical development, including FDA/EMA clearances and a Breakthrough Therapy Designation, further underscores the company's operational momentum.